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Dear Editor,
We read with great interest the study by 
Cheinquer et al.1 in a recent issue of the 
Brazilian Journal of Infectious Diseases where 
they suggest that patients with cirrhosis due 
to hepatitis C virus (HCV) who achieved 
sustained virological response (SVR) had 
significantly lower incidence of hepatocellular 
carcinoma (HCC) when compared to those 
without treatment response. Also, inter-
feron treatment after curative resection or 
ablation of HCC in HCV related cirrhotics 
prevents HCC recurrence and improves sur-
vival, especially for patients with SVR, had 
been reported in a recent meta-analysis.2
However, a large-scale randomized con-
trolled trial (the HALT-C study) showed no 
significant difference in the incidence of 
HCC between patients on maintenance in-
terferon therapy and those without.3 The 
reason for the discrepant results in studies 
needs further clarification, together with 
analysis of the difference in incidence rates 
of HCC among cirrhotic patients. 
A prospective study was carried out to in-
vestigate the efficacy and safety of standard in-
terferon with a low progressive dosage regimen 
in combination with ribavirin in patients with 
HCV-related decompensated cirrhosis in our 
center since 2008. Two patients with HCV-re-
lated decompensated cirrhosis developed HCC 
after successful antiviral therapy. Both of them 
had been treated with standard interferon α-2b 
(3 Mu, every other day) and ribavirin (800 
mg/d) for 48 weeks. The first case (62-year-
old, female, Child-Pugh score 8 and genotype 
1b) developed a hepatocellular carcinoma at 
month 6 after achieving SVR. The second case 
(53-year-old, male, Child-Pugh score 9 and 
genotype 2a) achieved early virologic response 
and end of treatment response, a single 2 cm 
tumor nodule was detected by enhanced CT 
liver scan three months after end of treatment. 
Both patients underwent transcatheter arte-
rial chemoembolization due to expansion and 
shortage of organs.
Although SVR is associated with long term 
good prognosis for patients with HCV infec-
tion,4,5 two out of 28 cirrhotic patients devel-
oped HCC compared to none of 146 patients 
without cirrhosis during follow-up for a mean 
of 47 months after SVR.5 It therefore remains 
uncertain if persistent virologic suppression to 
undetectable levels of HCV RNA impacts the 
risk of developing HCC in patients with severe 
hepatic fibrosis. Since cirrhosis is an independ-
ent risk factor for HCC, a vigilant monitoring 
of patients with HCV-related cirrhosis (com-
pensated and decompensated) should be man-
datory, even if SVR has been achieved after re-
ceiving interferon-based therapy.
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